Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
McKinsey
UBS
Julphar
AstraZeneca
Fuji
Harvard Business School
Johnson and Johnson
Cipla

Generated: February 23, 2018

DrugPatentWatch Database Preview

Galen Uk Company Profile

« Back to Dashboard

Summary for Galen Uk
International Patents:217
US Patents:18
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Galen Uk

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Galen Uk ADASUVE loxapine POWDER;INHALATION 022549-001 Dec 21, 2012 RX Yes Yes 8,173,107 ➤ Sign Up Y ➤ Sign Up
Galen Uk ADASUVE loxapine POWDER;INHALATION 022549-001 Dec 21, 2012 RX Yes Yes 9,440,034 ➤ Sign Up Y ➤ Sign Up
Galen Uk ADASUVE loxapine POWDER;INHALATION 022549-001 Dec 21, 2012 RX Yes Yes 7,090,830 ➤ Sign Up Y ➤ Sign Up
Galen Uk ADASUVE loxapine POWDER;INHALATION 022549-001 Dec 21, 2012 RX Yes Yes 7,052,679 ➤ Sign Up Y ➤ Sign Up
Galen Uk ADASUVE loxapine POWDER;INHALATION 022549-001 Dec 21, 2012 RX Yes Yes 9,687,487 ➤ Sign Up Y Y ➤ Sign Up
Galen Uk ADASUVE loxapine POWDER;INHALATION 022549-001 Dec 21, 2012 RX Yes Yes 7,078,020 ➤ Sign Up Y ➤ Sign Up
Galen Uk ADASUVE loxapine POWDER;INHALATION 022549-001 Dec 21, 2012 RX Yes Yes 7,458,374 ➤ Sign Up Y ➤ Sign Up
Galen Uk ADASUVE loxapine POWDER;INHALATION 022549-001 Dec 21, 2012 RX Yes Yes 7,601,337 ➤ Sign Up Y ➤ Sign Up
Galen Uk ADASUVE loxapine POWDER;INHALATION 022549-001 Dec 21, 2012 RX Yes Yes 7,585,493 ➤ Sign Up Y ➤ Sign Up
Galen Uk ADASUVE loxapine POWDER;INHALATION 022549-001 Dec 21, 2012 RX Yes Yes 9,370,629 ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for Galen Uk

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,498,019 Delivery of compounds for the treatment of headache through an inhalation route ➤ Sign Up
7,087,218 Delivery of diazepam through an inhalation route ➤ Sign Up
7,008,615 Delivery of anti-migraine compounds through an inhalation route ➤ Sign Up
7,078,016 Delivery of caffeine through an inhalation route ➤ Sign Up
7,108,847 Delivery of muscle relaxants through an inhalation route ➤ Sign Up
7,470,421 Delivery of diazepam through an inhalation route ➤ Sign Up
6,783,753 Delivery of antidepressants through an inhalation route ➤ Sign Up
6,805,854 Delivery of sumatriptan, frovatriptan or naratriptan through an inhalation route ➤ Sign Up
6,682,716 Delivery of aerosols containing small particles through an inhalation route ➤ Sign Up
7,033,575 Delivery of physiologically active compounds through an inhalation route ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Galen Uk Drugs

Supplementary Protection Certificates for Galen Uk Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0609 Netherlands ➤ Sign Up PRODUCT NAME: LOXAPINE; REGISTRATION NO/DATE: EU/1/13/823/001-002 20130220
2013 00046 Denmark ➤ Sign Up PRODUCT NAME: LOXAPIN; REG. NO/DATE: EU/1/13/823/001-002 20130220
00609 Netherlands ➤ Sign Up PRODUCT NAME: LOXAPINE; REGISTRATION NO/DATE: EU/1/13/823/001-002 20130220
90040-2 Sweden ➤ Sign Up PRODUCT NAME: LOXAPIN; REG. NO/DATE: EU/1/13/823/001 20130220
3 Finland ➤ Sign Up
2013 00046 Denmark ➤ Sign Up PRODUCT NAME: LOXAPIN; REG. NO/DATE: EU/1/13/823/001-002 20130220
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
Johnson and Johnson
QuintilesIMS
Cipla
Queensland Health
Harvard Business School
Argus Health
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot